GSK (GSK) announced the marketing authorization of Exdensur by the UK’s Medicines and Healthcare products Regulatory Agency. In the UK, Exdensur is now approved in two indications: as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype who are inadequately controlled on maximum moderate-dose or high-dose inhaled corticosteroids plus another asthma controller; as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK’s New Study on Belantamab Mafodotin: A Potential Game-Changer for Multiple Myeloma Treatment
- GSK’s SPHERE Study Completes: A New Horizon for Pediatric HES Treatment
- GSK’s IPF Drug Study Terminated: Implications for Investors
- GSK announced the CHMP of EMA recommended approval of depemokimab
- GSK announces CHMP of EMA recommended approval of Nucala